Navigation Links
Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
Date:1/28/2009

Product is Japan's first second-generation drug-eluting stent

NATICK, Mass., Jan. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System. The Company plans to launch the product as soon as reimbursement approval is granted, which is expected in the coming weeks.

TAXUS Liberte is the only second-generation drug-eluting stent approved for use in Japan. Design improvements over the Company's first-generation TAXUS(R) Express2(TM) Stent include thinner struts to allow better stent deliverability and conformability, as well as a more uniform stent geometry for consistent lesion coverage and drug distribution.

"The TAXUS Liberte Stent is the latest advance in drug-eluting stent technology for Japan," said Donald Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "Its safety and efficacy have been well demonstrated in multiple clinical studies and years of clinical use."

"We are very pleased with this approval, which provides access to proven technology to Japanese physicians and their patients," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "We are committed to continuing to provide the most innovative products and therapies to the Japanese market."

The TAXUS Liberte Stent uses proven paclitaxel-eluting technology, which has been evaluated by the industry's most extensive randomized, controlled clinical trial program, and studied in 35,000 real-world patients enrolled in post-approval registries. More than 4.6 million TAXUS Stent Systems have been implanted globally.

The TAXUS Liberte Stent will replace the TAXUS Express2 Stent, which was launched in Japan in May 2007. It has been approved for sale in the United States, Europe and other international markets.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACTS:
    Paul Donovan
    Media Relations
    Boston Scientific Corporation
    508-650-8541 (office)
    508-667-5165 (mobile)

    Larry Neumann
    Investor Relations
    Boston Scientific Corporation
    508-650-8696 (office)


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
2. Boston Scientific Acquires Labcoat Limited
3. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
4. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
5. Boston Scientific to Participate in Piper Jaffray Health Care Conference
6. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
7. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
8. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
9. InterMune to Present at Deutsche Bank Biotech Boston Confab
10. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
11. Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
(Date:2/3/2016)... Feb. 3, 2016 Harvard Apparatus Regenerative ... company developing bioengineered organ implants for life-threatening conditions ... that CEO Jim McGorry , will present ... on Tuesday, February 9, 2016 at 8:00 ... . HART,s presentation will be webcast live ...
(Date:2/3/2016)... ON (PRWEB) , ... February 03, 2016 , ... ... and validating a series of potential targets (epitopes) specific to misfolded, propagating strains ... targets to create specific monoclonal antibody therapeutics for Alzheimer’s. , Following on from ...
(Date:2/3/2016)... Feb. 3, 2016  Silk Therapeutics, Inc., today announced the ... Therapeutics has now raised a total of $10.25 million in ... company. The Series A2 round was led by existing investor ... with participation from new investors Lear Corporation and Highland Consumer ... P. Disney ; Richard Sackler , MD, with Summer ...
Breaking Biology Technology:
(Date:1/20/2016)... A market that just keeps on growing. ... explosion in genomics knowledge. Learn all about it in ... of dynamic trends are pushing market growth and company ... pharmacogenomics - pathogen evolution - next generation sequencing - ... understanding of the role of genetic material in Disease ...
(Date:1/15/2016)... Jan. 15, 2016 Recent publicized breaches in ... find new ways to ensure data security and user ... and Android that ties a user,s ... it into a hardware authorization token. Customer service agents ... fingerprint on their KodeKey enabled device to verify their ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the ... nearly 10,000 retail locations, web and mobile, today ... $40 million from existing investors. ... be devoted to further innovate higi,s health platform ... and web portal – including expanding services and ...
Breaking Biology News(10 mins):